Compass Pathways bets on fast FDA review for psilocybin depression drug
Compass Pathways has wrapped its FDA application for COMP360, a synthetic psilocybin treatment for treatment-resistant depression, after two Phase 3 trials in nearly 900 patients hit positive results. CEO Kabir Nath says a National Priority Voucher could speed review, with a launch targeted for the first half of next year.
- Original source: finance.yahoo.com.
- The source published it on Nov 22, 2026 at 6:11 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Compass Pathways has finished its FDA application for COMP360, its experimental synthetic psilocybin treatment for treatment-resistant depression. The filing covers two Phase 3 trials that enrolled close to 900 patients and delivered statistically significant positive results, backed by an earlier Phase 2b study. CEO Kabir Nath, speaking at a Jefferies event, said the company expects to launch in the first half of next year, with readiness by the end of this year if regulators sign off.
A Commissioner's National Priority Voucher is now in hand, and Nath said it could set up a rapid FDA review. Compass already had a rolling submission and review agreement before the voucher arrived, he added. Jefferies analyst Andrew Tsai pegged Nov. 9 as the date the application was completed.
Nath said the FDA had been reviewing submitted modules all along, and that Compass has no reason to think the agency is walking back its stated aim of finishing the review within one to two months of the completed submission. He also expects the application to be accepted with a PDUFA date, though he doesn't know when that lands. Whenever it's assigned, he said, it could reflect a standard six-month priority review that the FDA might beat.
For the commercial push, Compass plans to ride existing SPRAVATO treatment centers, with 9,000 or more sites expected by launch. Nath estimated COMP360 would need two to four doses a year per patient. He said the company expects to price it at a premium to SPRAVATO, while warning that insurers may drag their feet on coverage at first. Everything hinges on approval and rescheduling.
TopicsCompass Pathways · COMP360 · Kabir Nath · FDA · Jefferies · Andrew Tsai · SPRAVATO · NASDAQ: CMPS
Source: finance.yahoo.com
Written by AI from verified reporting.
More stories
- Health & science ruibao.news 2 viewsFDA Rejects Akeso's Ivonescimab, Citing China-Heavy Trial Data
- Health & science theguardian.com Caught by @pipio 2 viewsTrusted Messengers Hold the Key to Stopping the Amish Measles Outbreak
- Health & science simplywall.st 2 sources 2 viewsAlnylam Notches Seventh FDA Approval as Livsayis Clears Myasthenia Gravis
- Health & science sciencealert.com Caught by @ajayy30 1 viewKids With More Screen Time Scored Better on Teen Brain Tests, 8-Year Study Finds

